Melanoma Genome Project will map out future for skin cancer cures

Melanoma cancer researchNSW Minister for Health and Medical Research, the Hon. Jillian Skinner has today officially launched the Australian Melanoma Genome Project, an ambitious cancer research program that aims to identify the common gene mutations that lead to melanoma.

The $5.5 million project could take 2-5 years and is being undertaken by a research coalition of teams from the Melanoma Institute Australia, the University of Sydney, Westmead Millennium Institute, Royal Prince Alfred Hospital, NSW Health Pathology and the Queensland Institute of Medical Research.

More than 500 melanoma tumour samples will be screened and analysed in order to determine common genetic characteristics for this most deadly and prevalent type of cancer. Continue reading “Melanoma Genome Project will map out future for skin cancer cures”

Advanced Melanoma – New treatment has the potential to double survival time

One of the first new melanoma treatments to be released in over a decade could double the average survival time for melanoma patients.

The drug, Vemurafenib, was approved by regulators in the United States and Australia last year after studies showed that in a significant number of patients with advanced melanoma, the cancers either stopped growing or shrank after receiving the treatment.

The latest research now shows that in many cases, treatment with Vemurafenib has doubled cancer patients’ survival period from 6-10 months to approximately 16 months. Continue reading “Advanced Melanoma – New treatment has the potential to double survival time”

ACRF awards $9 million to world-class cancer research!

Last night the ACRF was proud to award $9 million in grants to three cutting-edge cancer research centres who are doing truly fantastic work here in Australia.

The awardees were selected after a thorough investigation by our Medical Research Advisory Committee (which consists of 13 esteemed Australian cancer researchers and is chaired by Professor Ian Frazer, co-creator of the cervical cancer vaccine).

In May of this year, ACRF received a total of 16 applicants for its cancer research grants. From these candidates, five were selected for further assessment , and yesterday, having conducted extensive site visits and interviews, the Committee made their final recommendations to the ACRF Board of Trustees.

The grants will be used exclusively to fund state-of-the-art technologies and facilities which speed up discoveries in our fight against cancer – ultimately working to save lives by saving time. Continue reading “ACRF awards $9 million to world-class cancer research!”